Cargando…
SliC is a surface-displayed lipoprotein that is required for the anti-lysozyme strategy during Neisseria gonorrhoeae infection
Lysozymes are nearly omnipresent as the first line of immune defense against microbes in animals. They exert bactericidal action through antimicrobial peptide activity and peptidoglycan hydrolysis. Gram-negative bacteria developed several weapons to battle lysozymes, including inhibitors of c-type l...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033465/ https://www.ncbi.nlm.nih.gov/pubmed/29975784 http://dx.doi.org/10.1371/journal.ppat.1007081 |
_version_ | 1783337710699675648 |
---|---|
author | Zielke, Ryszard A. Le Van, Adriana Baarda, Benjamin I. Herrera, Marco F. Acosta, Christopher J. Jerse, Ann E. Sikora, Aleksandra E. |
author_facet | Zielke, Ryszard A. Le Van, Adriana Baarda, Benjamin I. Herrera, Marco F. Acosta, Christopher J. Jerse, Ann E. Sikora, Aleksandra E. |
author_sort | Zielke, Ryszard A. |
collection | PubMed |
description | Lysozymes are nearly omnipresent as the first line of immune defense against microbes in animals. They exert bactericidal action through antimicrobial peptide activity and peptidoglycan hydrolysis. Gram-negative bacteria developed several weapons to battle lysozymes, including inhibitors of c-type lysozymes in the MliC/PliC family and the Neisseria adhesin complex protein (ACP). Until the recent discovery of ACP, no proteinaceous lysozyme inhibitors were reported for the genus Neisseria, including the important human pathogen N. gonorrhoeae. Here, we describe a previously unrecognized gonococcal virulence mechanism involving a protein encoded by the open reading frame ngo1063 that acts to counteract c-type Iysozyme and provides a competitive advantage in the murine model of gonorrhea. We named this protein SliC as a surface-exposed lysozyme inhibitor of c-type lysozyme. SliC displays low overall primary sequence similarity to the MliC/PliC inhibitors, but we demonstrate that it has a parallel inhibitory mechanism. Our studies provide the first evidence that bacterial proteinaceous lysozyme inhibitors protect against host lysozyme during infection based on lack of attenuation of the ΔsliC mutant in lysozyme knock-out mice, and that the conserved residues involved in lysozyme inhibition, S83 and K103, are functionally indispensable during infection in wild type mice. Recombinant SliC completely abrogated the lytic activity of human and chicken c-type lysozymes, showing a preference towards human lysozyme with an IC(50) of 1.85 μM and calculated K(D) value of 9.2 ± 1.9 μM. In contrast, mutated SliC bearing S83A and K103A substitutions failed to protect fluorescein-labeled cell-wall from lysozyme-mediated hydrolysis. Further, we present data revealing that SliC is a surface-displayed lipoprotein released in membrane vesicles that is expressed throughout all phases of growth, in conditions relevant to different niches of the human host, and during experimental infection of the murine genital tract. SliC is also highly conserved and expressed by diverse gonococcal isolates as well as N. meningitidis, N. lactamica, and N. weaveri. This study is the first to highlight the importance of an anti-lysozyme strategy to escape the innate immune response during N. gonorrhoeae infection. |
format | Online Article Text |
id | pubmed-6033465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-60334652018-07-19 SliC is a surface-displayed lipoprotein that is required for the anti-lysozyme strategy during Neisseria gonorrhoeae infection Zielke, Ryszard A. Le Van, Adriana Baarda, Benjamin I. Herrera, Marco F. Acosta, Christopher J. Jerse, Ann E. Sikora, Aleksandra E. PLoS Pathog Research Article Lysozymes are nearly omnipresent as the first line of immune defense against microbes in animals. They exert bactericidal action through antimicrobial peptide activity and peptidoglycan hydrolysis. Gram-negative bacteria developed several weapons to battle lysozymes, including inhibitors of c-type lysozymes in the MliC/PliC family and the Neisseria adhesin complex protein (ACP). Until the recent discovery of ACP, no proteinaceous lysozyme inhibitors were reported for the genus Neisseria, including the important human pathogen N. gonorrhoeae. Here, we describe a previously unrecognized gonococcal virulence mechanism involving a protein encoded by the open reading frame ngo1063 that acts to counteract c-type Iysozyme and provides a competitive advantage in the murine model of gonorrhea. We named this protein SliC as a surface-exposed lysozyme inhibitor of c-type lysozyme. SliC displays low overall primary sequence similarity to the MliC/PliC inhibitors, but we demonstrate that it has a parallel inhibitory mechanism. Our studies provide the first evidence that bacterial proteinaceous lysozyme inhibitors protect against host lysozyme during infection based on lack of attenuation of the ΔsliC mutant in lysozyme knock-out mice, and that the conserved residues involved in lysozyme inhibition, S83 and K103, are functionally indispensable during infection in wild type mice. Recombinant SliC completely abrogated the lytic activity of human and chicken c-type lysozymes, showing a preference towards human lysozyme with an IC(50) of 1.85 μM and calculated K(D) value of 9.2 ± 1.9 μM. In contrast, mutated SliC bearing S83A and K103A substitutions failed to protect fluorescein-labeled cell-wall from lysozyme-mediated hydrolysis. Further, we present data revealing that SliC is a surface-displayed lipoprotein released in membrane vesicles that is expressed throughout all phases of growth, in conditions relevant to different niches of the human host, and during experimental infection of the murine genital tract. SliC is also highly conserved and expressed by diverse gonococcal isolates as well as N. meningitidis, N. lactamica, and N. weaveri. This study is the first to highlight the importance of an anti-lysozyme strategy to escape the innate immune response during N. gonorrhoeae infection. Public Library of Science 2018-07-05 /pmc/articles/PMC6033465/ /pubmed/29975784 http://dx.doi.org/10.1371/journal.ppat.1007081 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article Zielke, Ryszard A. Le Van, Adriana Baarda, Benjamin I. Herrera, Marco F. Acosta, Christopher J. Jerse, Ann E. Sikora, Aleksandra E. SliC is a surface-displayed lipoprotein that is required for the anti-lysozyme strategy during Neisseria gonorrhoeae infection |
title | SliC is a surface-displayed lipoprotein that is required for the anti-lysozyme strategy during Neisseria gonorrhoeae infection |
title_full | SliC is a surface-displayed lipoprotein that is required for the anti-lysozyme strategy during Neisseria gonorrhoeae infection |
title_fullStr | SliC is a surface-displayed lipoprotein that is required for the anti-lysozyme strategy during Neisseria gonorrhoeae infection |
title_full_unstemmed | SliC is a surface-displayed lipoprotein that is required for the anti-lysozyme strategy during Neisseria gonorrhoeae infection |
title_short | SliC is a surface-displayed lipoprotein that is required for the anti-lysozyme strategy during Neisseria gonorrhoeae infection |
title_sort | slic is a surface-displayed lipoprotein that is required for the anti-lysozyme strategy during neisseria gonorrhoeae infection |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033465/ https://www.ncbi.nlm.nih.gov/pubmed/29975784 http://dx.doi.org/10.1371/journal.ppat.1007081 |
work_keys_str_mv | AT zielkeryszarda slicisasurfacedisplayedlipoproteinthatisrequiredfortheantilysozymestrategyduringneisseriagonorrhoeaeinfection AT levanadriana slicisasurfacedisplayedlipoproteinthatisrequiredfortheantilysozymestrategyduringneisseriagonorrhoeaeinfection AT baardabenjamini slicisasurfacedisplayedlipoproteinthatisrequiredfortheantilysozymestrategyduringneisseriagonorrhoeaeinfection AT herreramarcof slicisasurfacedisplayedlipoproteinthatisrequiredfortheantilysozymestrategyduringneisseriagonorrhoeaeinfection AT acostachristopherj slicisasurfacedisplayedlipoproteinthatisrequiredfortheantilysozymestrategyduringneisseriagonorrhoeaeinfection AT jerseanne slicisasurfacedisplayedlipoproteinthatisrequiredfortheantilysozymestrategyduringneisseriagonorrhoeaeinfection AT sikoraaleksandrae slicisasurfacedisplayedlipoproteinthatisrequiredfortheantilysozymestrategyduringneisseriagonorrhoeaeinfection |